TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Anadys Bounces Back With Release of Positive Drug Data EP Vantage submits:After a safety scare last year, Anadys Pharmaceuticals’ (ANDS) trials of its hepatitis C candidate ANA598 appear to be back on track with a series of positive interim results in phase II trials (Anadys' bubble burst by lack of partner, June 5, 2009). The burning issue for the California firm, however, is its urgent need to partner the drug before it runs out of cash.With the aim of cutting its cash burn by $4m-$5m last summer, Anadys went through a restructuring that involved trimming its workforce by 40% and suspending work on a second hep C candidate, ANA773. But it remains a company with just $15.5m in cash at the end of March and a burn rate of $4m-$5m per quarter, meaning phase III will not happen without a partner or new investment.Complete Story » seekingalpha.com |
PPD and Microsoft to Deliver Innovative REMS Solution Based on Microsoft Technologies (Business Wire) WILMINGTON, N.C.----PPD, Inc. and Microsoft Corp. today announced they have entered into an agreement to jointly implement an innovative technology solution designed to improve efficiency in managing U.S. us.rd.yahoo.com |
Adventrx Pharma Sets Out to Improve Current Cancer Drugs Douglas Cress submits:By vandersonChemotherapy drugs are powerful anti-cancer agents, but they can also cause adverse side effects such as rashes, nausea, and allergic reactions. Reformulating a popular drug offers pharmaceutical companies the opportunity to preserve a drug’s known strengths while reducing its weaknesses. Although reformulation can be a way for pharmaceutical companies to get more mileage out of a drug that’s about to go off-patent, it can benefit the patient as well. With a reformulation, patients receive a wider range of treatment options coupled with the reassuring familiarity of an existing, well-established drug. Reformulation is the main business of Adventrx Pharmaceuticals (ANX). The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere. In an October 2009 interview with the Wall Street Transcript, Adventrx CEO Brian M. Culley described the company’s approach as a “faster, lower-cost, lower-risk drug development strategy.”Complete Story » seekingalpha.com |
Boehringer Halts 'Pink Viagra' Germany's Boehringer Ingelheim said it has stopped developing an oral pill designed to treat low-sex drive in women after failing to convince U.S authorities that the medicine works. online.wsj.com |
PAREXEL Consulting Releases Annual Analysis of FDA New Drug Review Trends [PR Newswire] - PAREXEL Consulting, a business unit of PAREXEL International and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released a new white paper entitled Drug Innovation, Approval, Market Access, and the "New Normal": Emerging FDA Review Outcome Trends for New Drugs. Â Exploring trends in the review of new molecular entities , as well as first-cycle approval and priority designation rates, PAREXEL Consulting's analysis indicates that there is a "new normal" emerging in the drug review and approval process. us.rd.yahoo.com |